TABLE 2.

Change of systolic BP from baseline at Week 8 (additional analysis)

	Quarter‐dose (n = 25)	Third‐dose (n = 23)	Half‐dose (n = 24)
Baseline
Number of subjects	25	23	24
Mean ± SD	151.77 ± 12.65	150.32 ± 12.61	153.34 ± 10.58
Median	151.50	147.50	153.10
Minimum–maximum	131.50–175.70	132.00–175.00	132.00–173.00
Week 8
Number of subjects	25	23	24
Mean ± SD	132.90 ± 20.79	135.77 ± 10.84	133.79 ± 12.70
Median	130.00	135.50	135.50
Minimum–maximum	101.50–183.50	121.30–159.00	116.50–161.50
Change from baseline to Week 8
Number of subjects	25	23	24
Mean ± SD	−18.87 ± 16.87	−14.55 ± 14.84	−19.55 ± 14.75
Median	−18.50	−13.00	−21.75
Minimum–maximum	−44.00–18.30	−52.50–12.00	−45.00–13.20
Model‐adjusted change from baseline to Week 8
Number of subjects	25	23	24
LS mean ± SE	−19.07 ± 2.97	−15.31 ± 3.34	−19.30 ± 3.03
95% Confidence interval	[−25.01, −13.13]	[−21.97, −8.64]	[−25.36, −13.24]
P‐value	<.0001	<.0001	<.0001
Treatment differencea
Difference of LS means ± SE		3.76 ± 4.62	−.23 ± 4.26
95% Confidence interval		[−5.47, 13.00]	[−8.73, 8.27]
P‐valueb		.4187	.9575
Treatment differencec
Difference of LS means ± SE			−3.99 ± 4.51
95% Confidence interval			[−13.00, 5.02]
P‐valueb			.3796

Abbreviations: BP, blood pressure; LS mean, least squares mean; MSSBP, mean sitting systolic BP; SD, standard deviation; SE, standard error.

^aTreatment difference: third‐dose – quarter‐dose, half‐dose – quarter‐dose.

^bAnalysis of covariance: change = baseline MSSBP + treatment + age + gender + age*gender.

^cTreatment difference: half‐dose – third‐dose.